1. Introduction
thrombosis, death, CAD, coronary artery disease, ACS
THROMBOSIS, ACUTE CORONARY SYNDROMES, CORONARY ARTERY DISEASE, SECONDARY, EVENTS, CORONARY ARTERY DISEASE, CAD
Coronary artery disease (CAD) is one of the most common causes of death worldwide [Dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor (e.g., clopidogrel, prasugrel, and ticagrelor) and aspirin are considered the cornerstone of secondary prevention in patients with acute coronary syndromes (ACS) with or without STEMI and patients with stable coronary artery disease undergoing PCI [Clopidogrel is a prodrug that requires hepatic conversion to be activated, which leads to a delay in the onset of action. The effectiveness of platelet inhibition by clopidogrel varies among individuals, and more than one-third of the patients are considered “clopidogrel nonresponders” who achieve minimal platelet inhibition when using this medication [Ticagrelor, a reversible P2Y12 receptor antagonist, does not require hepatic activation. However, the PLATelet inhibition and patient outcomes (PLATO) trial showed that ticagrelor has significant benefits compared to clopidogrel in reducing total death, averting stent thrombosis, and preventing cardiovascular events [Due to the mentioned controversies, this article aimed to compare two P2Y12 inhibitors, clopidogrel and ticagrelor, regarding their efficacy and side effects among patients who underwent PCI.